Donghui Wang1, Cen Chen2, Yanli Gu1, Wanjun Lu3, Ping Zhan3, Hongbing Liu3, Tangfeng Lv3, Yong Song3, Fang Zhang1,3. 1. Department of Respiratory and Critical Care Medicine, Jinling Hospital, Nanjing Medical University, Nanjing, China. 2. Department of Respiratory and Critical Care Medicine, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University, Nanjing, China. 3. Department of Respiratory and Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Abstract
BACKGROUND: Immune-related adverse events (irAEs) have been reported to be associated with the efficacy of immunotherapy. Herein, we conducted a meta-analysis to demonstrate that irAEs could predict the efficacy of immune checkpoint inhibitors (ICIs) in lung cancer patients. METHODS: Literature on the correlation between irAEs and the efficacy of immunotherapy in lung cancer patients were searched to collect the data on objective response rate (ORR), overall survival (OS), or progression-free survival (PFS) of the patients. These data were incorporated into the meta-analysis. RESULTS: A total of 34 records encompassing 8,115 patients were examined in this study. The irAEs occurrence was significantly associated with higher ORR {risk ratio (RR): 2.43, 95% confidence interval (CI) [2.06-2.88], p < 0.00001} and improved OS {hazard ratio (HR): 0.51, 95% CI [0.43-0.61], p < 0.00001}, and PFS (HR: 0.50, 95% CI [0.44-0.57], p < 0.00001) in lung cancer patients undergoing ICIs. Subgroup analysis revealed that OS was significantly longer in patients who developed dermatological (OS: HR: 0.53, 95%CI [0.42-0.65], p < 0.00001), endocrine (OS: HR: 0.55, 95%CI [0.45-0.67], p < 0.00001), and gastrointestinal irAEs (OS: HR: 0.58, 95%CI [0.42-0.80], p = 0.0009) than in those who did not. However, hepatobiliary, pulmonary, and high-grade (≥3) irAEs were not correlated with increased OS and PFS. CONCLUSION: The occurrence of irAEs in lung cancer patients, particularly dermatological, endocrine, and gastrointestinal irAEs, is a predictor of enhanced ICIs efficacy.
BACKGROUND: Immune-related adverse events (irAEs) have been reported to be associated with the efficacy of immunotherapy. Herein, we conducted a meta-analysis to demonstrate that irAEs could predict the efficacy of immune checkpoint inhibitors (ICIs) in lung cancer patients. METHODS: Literature on the correlation between irAEs and the efficacy of immunotherapy in lung cancer patients were searched to collect the data on objective response rate (ORR), overall survival (OS), or progression-free survival (PFS) of the patients. These data were incorporated into the meta-analysis. RESULTS: A total of 34 records encompassing 8,115 patients were examined in this study. The irAEs occurrence was significantly associated with higher ORR {risk ratio (RR): 2.43, 95% confidence interval (CI) [2.06-2.88], p < 0.00001} and improved OS {hazard ratio (HR): 0.51, 95% CI [0.43-0.61], p < 0.00001}, and PFS (HR: 0.50, 95% CI [0.44-0.57], p < 0.00001) in lung cancer patients undergoing ICIs. Subgroup analysis revealed that OS was significantly longer in patients who developed dermatological (OS: HR: 0.53, 95%CI [0.42-0.65], p < 0.00001), endocrine (OS: HR: 0.55, 95%CI [0.45-0.67], p < 0.00001), and gastrointestinal irAEs (OS: HR: 0.58, 95%CI [0.42-0.80], p = 0.0009) than in those who did not. However, hepatobiliary, pulmonary, and high-grade (≥3) irAEs were not correlated with increased OS and PFS. CONCLUSION: The occurrence of irAEs in lung cancer patients, particularly dermatological, endocrine, and gastrointestinal irAEs, is a predictor of enhanced ICIs efficacy.
Authors: Biagio Ricciuti; Carlo Genova; Andrea De Giglio; Maria Bassanelli; Maria Giovanna Dal Bello; Giulio Metro; Marta Brambilla; Sara Baglivo; Francesco Grossi; Rita Chiari Journal: J Cancer Res Clin Oncol Date: 2018-12-01 Impact factor: 4.553
Authors: Hye In Kim; Mijin Kim; Se-Hoon Lee; So Young Park; Young Nam Kim; Hosu Kim; Min Ji Jeon; Tae Yong Kim; Sun Wook Kim; Won Bae Kim; Sang-We Kim; Dae Ho Lee; Keunchil Park; Myung-Ju Ahn; Jae Hoon Chung; Young Kee Shong; Won Gu Kim; Tae Hyuk Kim Journal: Oncoimmunology Date: 2017-09-21 Impact factor: 8.110
Authors: J C Osorio; A Ni; J E Chaft; R Pollina; M K Kasler; D Stephens; C Rodriguez; L Cambridge; H Rizvi; J D Wolchok; T Merghoub; C M Rudin; S Fish; M D Hellmann Journal: Ann Oncol Date: 2017-03-01 Impact factor: 32.976
Authors: Yangyang Xu; Bing Wan; Xi Chen; Ping Zhan; Yuan Zhao; Tianli Zhang; Hongbing Liu; Muhammad Zubair Afzal; Said Dermime; Steven N Hochwald; Paul Hofman; Hossein Borghaei; Dang Lin; Tangfeng Lv; Yong Song Journal: Transl Lung Cancer Res Date: 2019-08
Authors: Wouter Ouwerkerk; Mirjam van den Berg; Sanne van der Niet; Jacqueline Limpens; Rosalie M Luiten Journal: Melanoma Res Date: 2019-10 Impact factor: 3.599
Authors: Mariona Riudavets; Benjamin Wyplosz; Maria Rosa Ghigna; Angela Botticella; Pamela Abdayem; Pauline Pradere; Ines Kasraoui; Charles Roux; Cécile Le Pechoux; Camilo Garcia; David Planchard Journal: JTO Clin Res Rep Date: 2022-03-31